Analysed AUTONOMIX MEDICAL INC (AMIX:NASDAQ) News Sources
Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
08-04-2026
yahoo.com
Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
04-03-2026
yahoo.com
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation
25-02-2026
yahoo.com
Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation
19-02-2026
yahoo.com
Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
28-01-2026
yahoo.com
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium
09-01-2026
yahoo.com
What is the current price of AUTONOMIX MEDICAL INC (AMIX:NASDAQ)?
The current price of AUTONOMIX MEDICAL INC (AMIX:NASDAQ) is $0.3803.
AUTONOMIX MEDICAL INC (AMIX:NASDAQ) absolute price change since previous trading day?
The absolute price change of AUTONOMIX MEDICAL INC (AMIX:NASDAQ) since the previous trading day is $-0.0196.
AUTONOMIX MEDICAL INC (AMIX:NASDAQ) percentage price change since previous trading day?
The percentage price change of AUTONOMIX MEDICAL INC (AMIX:NASDAQ) since the previous trading day is -4.9012%.
What is the most recent average sentiment score for AUTONOMIX MEDICAL INC (AMIX:NASDAQ)?
The most recent average sentiment score for AUTONOMIX MEDICAL INC (AMIX:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for AUTONOMIX MEDICAL INC (AMIX:NASDAQ)?
The most recent sentiment for AUTONOMIX MEDICAL INC (AMIX:NASDAQ) is .
SEC-8K** Filing Available For AUTONOMIX MEDICAL INC (AMIX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.